Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease
Expert Reviews in Molecular Medicine · 2026
DOI: 10.1017/erm.2026.10072 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Reviews in Molecular Medicine, 2026. Verfasst von Busra Cetin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gene and Cell Therapy, Akdeniz University Faculty of Medicine, Türkiye. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Precision Medicine. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Spinal Muscular Atrophy (SMA) is caused by a deficiency of the survival motor neuron (SMN) protein due to loss of SMN1 and inefficient compensation by SMN2. This genetic architecture has driven the development of precision therapeutics. Over the past decade, SMA management has progressed from supportive care to RNA-based splicing modulation and gene replacement therapy.
Methods
This review analyzes the evolution of three therapeutic waves in SMA management: antisense oligonucleotides (nusinersen) for SMN2 splicing correction; systemic small-molecule splicing modifiers (risdiplam) addressing SMA as a multisystem disorder; and gene replacement therapy (onasemnogene abeparvovec), including recent intrathecal formulations expanding patient eligibility.
Results
Precision therapies have profoundly altered the disease trajectory, especially when administered presymptomatically. Nusinersen sustains splicing correction, risdiplam restores SMN across central and peripheral tissues, and gene replacement offers durable, one-time genetic correction. However, critical challenges persist regarding therapeutic durability, optimal treatment sequencing, systemic involvement, and long-term safety.
Conclusions
The evolution of SMA therapies has transformed neurogenetics. Clinical benchmarks have successfully shifted from reactive, symptomatic management to proactive, molecularly targeted precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gene and Cell Therapy, Akdeniz University Faculty of Medicine, Türkiye.
ORCID-Profile: Busra Cetin, Melike Aliciaslan, Ezgi Erbasan, Busra Cesur Ergun, Salih Sanlioglu
Zitieren
APA
Cetin, B., Aliciaslan, M., Erbasan, E., Cesur Ergun, B., & Sanlioglu, S. (2026). Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease. Expert Reviews in Molecular Medicine. https://doi.org/10.1017/erm.2026.10072
Vancouver
Cetin B, Aliciaslan M, Erbasan E, Cesur Ergun B, Sanlioglu S. Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease. Expert Reviews in Molecular Medicine. 2026. doi:10.1017/erm.2026.10072
BibTeX
@article{Cetin2026,
author = {Cetin, Busra and Aliciaslan, Melike and Erbasan, Ezgi and Cesur Ergun, Busra and Sanlioglu, Salih},
title = {Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease},
journal = {Expert Reviews in Molecular Medicine},
year = {2026},
doi = {10.1017/erm.2026.10072}
}
EUVIMED